PubMed Health⌕ Search

PubMed · 1413158

[Functional hypoglycemia. Fancy or fact?].

Abstract

Idiopathic reactive or functional hypoglycemia is not a recognised disease entity. It is defined solely on the basis of a history of hypoglycemic symptoms in everyday life, which can be relieved by food intake. However, the general opinion is that functional hypoglycemia exists, but it is not a frequent condition. The coincidence of a low blood glucose nadir and hypoglycemic symptoms in the hypoglycemic phase of the oral glucose tolerance test is not diagnostic of functional hypoglycemia. Endocrine dysfunction has never been demonstrated. The logical approach to the problem is to study blood glucose values during everyday life and at the onset of symptoms. This has been done in two controlled studies using reliable monitoring techniques. Low blood glucose concentrations during attacks could only be demonstrated in one of the studies and only in some of the subjects. Furthermore, the pattern of recorded symptoms was independent of the measured levels. Thus, these patients are probably not hypoglycemic in the true sense of the word. In a recent controlled but unblinded study, a higher blood glucose threshold for the onset of hypoglycemic symptoms was demonstrated in a group of patients with functional hypoglycemia. This, combined with a highly refined diet poor in fibre and starch, could provide symptomatic oscillations of blood glucose levels. However, much more research is needed in this field, before any conclusions are drawn.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O Snorgaard. 1992-08-31. [Functional hypoglycemia. Fancy or fact?].. https://pubmed.ncbi.nlm.nih.gov/1413158/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗